CJC-1295 research centers on a synthetic growth hormone-releasing hormone (GHRH) analogue that scientists study for its ability to stimulate the pituitary gland. Two versions dominate the literature: CJC-1295 with DAC and CJC-1295 without DAC, which researchers often label Modified GRF 1-29. Because the two forms behave so differently, understanding the distinction matters for anyone designing growth hormone axis experiments.
What Is CJC-1295?
CJC-1295 is a modified 29-amino-acid fragment of endogenous GHRH. Structural substitutions protect the peptide from rapid enzymatic breakdown, and therefore extend its stability compared with native GHRH. In laboratory models, it binds pituitary GHRH receptors and promotes the pulsatile release of growth hormone. In addition, researchers study it alongside growth hormone secretagogues to examine combined signalling on the somatotropic axis.
The Role of DAC (Drug Affinity Complex)
The key variable is the Drug Affinity Complex, or DAC. Chemically, it is a maleimidopropionic acid group that chemists attach to the peptide. Once attached, DAC binds covalently to circulating albumin. As a result, that binding dramatically extends the compound’s half-life, which early studies report at six to eight days. Consequently, CJC-1295 with DAC produces a sustained elevation in growth hormone and insulin-like growth factor 1 (IGF-1) levels in research models.
CJC-1295 Without DAC (Modified GRF 1-29)
CJC-1295 without DAC lacks the albumin-binding component. As a result, its half-life spans minutes rather than days. This short window means it mimics the natural, pulsatile pattern of growth hormone release more closely. For this reason, researchers often pair it with a GHRP such as Ipamorelin to study synergistic pulses. Because the effect clears quickly, they frequently use it in protocols that model tightly timed, physiologic bursts rather than continuous elevation.
Key Differences for Researchers
The two forms serve different experimental goals. With DAC, the compound delivers a long, steady “bleed” of growth hormone signalling, which helps when studying sustained IGF-1 exposure. Without DAC, by contrast, the compound produces sharp, brief spikes that resemble endogenous rhythm. Half-life is the defining distinction: days versus minutes. Ultimately, dosing frequency, receptor desensitization, and downstream IGF-1 kinetics all follow from this single structural choice. Both remain popular subjects in growth hormone axis research.
Handling and Storage in Research Settings
Like most peptides, suppliers ship CJC-1295 in a lyophilized form, so it requires reconstitution with bacteriostatic water before laboratory use. Freeze-dried vials stay stable when stored cool and dark. Meanwhile, researchers keep reconstituted solutions refrigerated. To control for purity, teams comparing the two forms typically source both from the same supplier. For broader work, the EhBuddy Peptides research catalogue offers a range of GHRH and secretagogue compounds.
Conclusion
In summary, CJC-1295 with DAC and without DAC share the same core peptide but differ by one decisive feature: the albumin-binding complex that turns a minutes-long half-life into a days-long one. Ultimately, that difference shapes every downstream research decision, from dosing cadence to the pattern of growth hormone release under study.
All products sold at EhBuddy Peptides are for laboratory and scientific research purposes only and are not intended for human or veterinary administration. EhBuddy Peptides ships all orders from within Canada.
